1 2 3 4 5 6 7	KAMALA D. HARRIS Attorney General of California GLORIA A. BARRIOS Supervising Deputy Attorney General KIMBERLEE D. KING Deputy Attorney General State Bar No. 141813 300 So. Spring Street, Suite 1702 Los Angeles, CA 90013 Telephone: (213) 897-2581 Facsimile: (213) 897-2804 Attorneys for Complainant			
8 9 10	BEFORE THE BOARD OF PHARMACY DEPARTMENT OF CONSUMER AFFAIRS STATE OF CALIFORNIA			
11	In the Matter of the Accusation Against: Case No. 3934			
12	ANAHIT EBROYAN			
13	7119 Varna Avenue North Hollywood, CA 91605 Pharmacy Technician Registration No. TCH 15182 A C C U S A T I O N			
14				
15	Respondent.			
16				
17	Complainant alleges:			
18	<u>PARTIES</u>			
19	1. Virginia Herold (Complainant) brings this Accusation solely in her official capacity			
20	as the Executive Officer of the Board of Pharmacy, Department of Consumer Affairs.			
21	2. On or about February 21, 1995, the Board of Pharmacy issued Pharmacy Technician			
22	Registration Number TCH 15182 to Anahit Ebroyan (Respondent). The Pharmacy Technician			
23	Registration was in full force and effect at all times relevant to the charges brought herein and			
24	will expire on February 28, 2013, unless renewed.			
25	<u>JURISDICTION</u>			
26	3. This Accusation is brought before the Board of Pharmacy (Board), Department of			
27	Consumer Affairs, under the authority of the following laws. All section references are to the			
28	Business and Professions Code unless otherwise indicated.			

28 ///

///

8. California Code of Regulations, title 16, section 1770, states:

"For the purpose of denial, suspension, or revocation of a personal or facility license pursuant to Division 1.5 (commencing with Section 475) of the Business and Professions Code, a crime or act shall be considered substantially related to the qualifications, functions or duties of a licensee or registrant if to a substantial degree it evidences present or potential unfitness of a licensee or registrant to perform the functions authorized by his license or registration in a manner consistent with the public health, safety, or welfare."

9. Section 125.3 of the Code states, in pertinent part, that the Board may request the administrative law judge to direct a licentiate found to have committed a violation or violations of the licensing act to pay a sum not to exceed the reasonable costs of the investigation and enforcement of the case.

DANGEROUS DRUGS

- 10. A. "Prevpac" is the brand name for a combination product containing Lansoprazote, Clarithromycin, and amoxicillin and is used to treat and prevent the return of ulcers caused by a certain type of bacteria. It is categorized as a "dangerous drug" pursuant to Business and Professions Code section 4022.
- B. "Truvada" is an anti-HIV drug in the nucleoside reverse transcriptase inhibitor family given in combination with other anti-HIV drugs. It is categorized as a "dangerous drug" pursuant to Business and Professions Code section 4022.
- C. "Seroquel" is the brand name for Quetipine, an antipsychotic drug. It is categorized as a "dangerous drug" pursuant to Business and Professions Code section 4022.
- D. "Viread" is an antiviral medication used to treat HIV in patients with Aids. It is categorized as a "dangerous drug" pursuant to Business and Professions Code section 4022.
- E. "Xeloda" is an orally-administered chemo-therapeutic agent used in the treatment of metastatic breast and colorectal cancers. It is categorized as a "dangerous drug" pursuant to Business and Professions Code section 4022.

- F. "Januvia" is a dipeptidyl peptidase-4 inhibitor used to lower blood sugar levels in patients with type 2 diabetes. It is categorized as a "dangerous drug" pursuant to Business and Professions Code section 4022.
- G. "Invega" is the brand name for Paliperidone, an antipsychotic medication used to treat schizophrenia. It is categorized as a "dangerous drug" pursuant to Business and Professions Code section 4022.
- H. "Aricept" is a cholinestebase inhibitor used to treat dementia associated with Alzheimer's disease. It is categorized as a "dangerous drug" pursuant to Business and Professions Code Section 4022.
- I. "Zyprexa" is the brand name for Olanzapine, an antipsychotic for the treatment of schizophrenia and bipolar disorder. It is categorized as a "dangerous drug" pursuant to Business and Professions Code section 4022.

FIRST CAUSE FOR DISCIPLINE

(Obtained Controlled Substances by Fraud or Deceit)

11. Respondent is subject to disciplinary action under sections 4300 and 4301 subdivisions (f), (j), and (o) of the Code, on the grounds of unprofessional conduct, for violating Health and Safety Code section 11173, subdivision (a), in that, on or about March 19, 2010, Respondent, while on duty at Omnicare Canoga Park, obtained dangerous drugs by stealing and/or attempting to steal the following dangerous drugs from her employer:

Drug	Quantity	Cost	AWP*
PrevPac	1x10	\$352.70	\$414.82
Truvada	2x60	\$1,956.06	\$2,236.00
Seroquel 200mg	2x200	\$1,687.40	\$2,125.76
Viread 300mg	2x60	\$1,327.46	\$1,543.08
Xeloda 500mg	1x120	\$2,789.53	\$3,408.79
Januvia 50mg	1x90	\$540.07	\$659.96
Invega 9mg Seroquel 30mg Aricept 5mg Zyprexa 15 mg	2x60	\$1,158.08	\$1,287.68
	2x120	\$1,327.46	\$1,672.32
	2x180	\$1,288.94	\$1,445.02
	2x160	\$1,240.86	<u>\$1,516.32</u>
Total *Average Wholesale Price		\$13,668.56	\$16,309.75

SECOND CAUSE FOR DISCIPLINE

(Unprofessional Conduct)

12. Respondent is subject to disciplinary action pursuant to section 4301 subdivision (a) in that while employed as a pharmacy technician, she committed acts of unprofessional conduct by stealing dangerous drugs from her employer and possessing these drugs without a prescription, as set forth above in paragraph 11.

PRAYER

WHEREFORE, Complainant requests that a hearing be held on the matters herein alleged, and that following the hearing, the Board of Pharmacy issue a decision:

- 1. Revoking or suspending Pharmacy Technician Registration Number TCH 15182, issued to Anahit Ebroyan
- 2. Ordering Anahit Ebroyan to pay the Board of Pharmacy the reasonable costs of the investigation and enforcement of this case, pursuant to Business and Professions Code section 125.3;
 - 3. Taking such other and further action as deemed necessary and proper.

Executive Officer Board of Pharmacy

Department of Consumer Affairs

State of California Complainant

LA2011600086 50864617.doc

28